Physician profile
Mark R Bowling
NPI 1710914098
$10,878.76
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,579 · 2020: $2,829 · 2021: $489 · 2022: $116 · 2023: $757 · 2024: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,720 · Food and Beverage: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,720.00 |
| Food and Beverage | $145.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $8,010.91 | 2019-2020 | |
| Medtronic, INC. | $2,250.87 | 2021-2024 | Illumisite |
| Abbvie INC. | $150.46 | 2021-2023 | Vraylar |
| Merck Sharp & Dohme LLC | $135.32 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $65.57 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $56.03 | 2019-2020 | |
| Haemonetics Corporation | $54.68 | 2023 | Teg6s Hemostasis System |
| Allergan, INC. | $42.82 | 2020 | |
| Lilly USA, LLC | $39.09 | 2019-2020 | |
| Celgene Corporation | $18.92 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $14.77 | 2021 | |
| La Jolla Pharmaceutical Company | $13.50 | 2020 | |
| Alexion Pharmaceuticals, INC. | $13.34 | 2020 | |
| Jazz Pharmaceuticals INC. | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bowling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.